Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
Amphista’s Platform Validated, Kymera Share Price Depressed
Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.
You may also be interested in...
Looking to take advantage of the cool reception private biotechs are receiving from the public markets, a leading European VC is targeting investments of up to €70m per deal in firms with undervalued late-stage assets.
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.